These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

159 related items for PubMed ID: 16800041

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Active antiviral T-lymphocyte response can be redirected against tumor cells by antitumor antibody x MHC/viral peptide conjugates.
    Cesson V, Stirnemann K, Robert B, Luescher I, Filleron T, Corradin G, Mach JP, Donda A.
    Clin Cancer Res; 2006 Dec 15; 12(24):7422-30. PubMed ID: 17189415
    [Abstract] [Full Text] [Related]

  • 23. MCP-3 (CCL7) delivered by parvovirus MVMp reduces tumorigenicity of mouse melanoma cells through activation of T lymphocytes and NK cells.
    Wetzel K, Struyf S, Van Damme J, Kayser T, Vecchi A, Sozzani S, Rommelaere J, Cornelis JJ, Dinsart C.
    Int J Cancer; 2007 Mar 15; 120(6):1364-71. PubMed ID: 17154174
    [Abstract] [Full Text] [Related]

  • 24. Effect of mouse strain and age on detection of mouse parvovirus 1 by use of serologic testing and polymerase chain reaction analysis.
    Besselsen DG, Wagner AM, Loganbill JK.
    Comp Med; 2000 Oct 15; 50(5):498-502. PubMed ID: 11099132
    [Abstract] [Full Text] [Related]

  • 25. Simian immunodeficiency virus vector pseudotypes differ in transduction efficiency and target cell specificity in brain.
    Liehl B, Hlavaty J, Moldzio R, Tonar Z, Unger H, Salmons B, Günzburg WH, Renner M.
    Gene Ther; 2007 Sep 15; 14(18):1330-43. PubMed ID: 17611586
    [Abstract] [Full Text] [Related]

  • 26. Response of weanling random-bred mice to inoculation with minute virus of mice.
    Smith AL.
    Lab Anim Sci; 1983 Feb 15; 33(1):37-9. PubMed ID: 6339807
    [Abstract] [Full Text] [Related]

  • 27. Humoral immunity and protection of mice challenged with homotypic or heterotypic parvovirus.
    Hansen GM, Paturzo FX, Smith AL.
    Lab Anim Sci; 1999 Aug 15; 49(4):380-4. PubMed ID: 10480642
    [Abstract] [Full Text] [Related]

  • 28. Neutralizing activity and cellular immune responses induced in mice after immunization with apoptotic HIV-1/murine leukemia virus infected cells.
    Hinkula J, Walther-Jallow L, Laurén A, Mäkitalo B, Oberg M, Wahren B, Fenyö EM, Spetz AL.
    Vaccine; 2009 Oct 30; 27(46):6424-31. PubMed ID: 19549607
    [Abstract] [Full Text] [Related]

  • 29. Effect of viral dose on neutralizing antibody response and transgene expression after AAV1 vector re-administration in mice.
    Petry H, Brooks A, Orme A, Wang P, Liu P, Xie J, Kretschmer P, Qian HS, Hermiston TW, Harkins RN.
    Gene Ther; 2008 Jan 30; 15(1):54-60. PubMed ID: 17960164
    [Abstract] [Full Text] [Related]

  • 30. Oncolytic virotherapy for malignant melanoma with herpes simplex virus type 1 mutant HF10.
    Watanabe D, Goshima F, Mori I, Tamada Y, Matsumoto Y, Nishiyama Y.
    J Dermatol Sci; 2008 Jun 30; 50(3):185-96. PubMed ID: 18226503
    [Abstract] [Full Text] [Related]

  • 31. A new recombinant vaccinia with targeted deletion of three viral genes: its safety and efficacy as an oncolytic virus.
    Yang S, Guo ZS, O'Malley ME, Yin X, Zeh HJ, Bartlett DL.
    Gene Ther; 2007 Apr 30; 14(8):638-47. PubMed ID: 17268533
    [Abstract] [Full Text] [Related]

  • 32. Genetic delivery of an anti-RSV antibody to protect against pulmonary infection with RSV.
    Skaricic D, Traube C, De B, Joh J, Boyer J, Crystal RG, Worgall S.
    Virology; 2008 Aug 15; 378(1):79-85. PubMed ID: 18556039
    [Abstract] [Full Text] [Related]

  • 33. Poly(D,L-lactic-co-glycolic acid) microsphere delivery of adenovirus for vaccination.
    Wang D, Molavi O, Lutsiak ME, Elamanchili P, Kwon GS, Samuel J.
    J Pharm Pharm Sci; 2007 Aug 15; 10(2):217-30. PubMed ID: 17706180
    [Abstract] [Full Text] [Related]

  • 34. A DNA vaccine constructed with human papillomavirus type 16 (HPV16) E7 and E6 genes induced specific immune responses.
    Yan Q, Cheung YK, Cheng SC, Wang XH, Shi M, Hu MH, Yong X.
    Gynecol Oncol; 2007 Jan 15; 104(1):199-206. PubMed ID: 17049969
    [Abstract] [Full Text] [Related]

  • 35. Respective roles of TNF-alpha and IL-6 in the immune response-elicited by adenovirus-mediated gene transfer in mice.
    Benihoud K, Esselin S, Descamps D, Jullienne B, Salone B, Bobé P, Bonardelle D, Connault E, Opolon P, Saggio I, Perricaudet M.
    Gene Ther; 2007 Mar 15; 14(6):533-44. PubMed ID: 17109009
    [Abstract] [Full Text] [Related]

  • 36. Assembly of trans-encapsidated recombinant viral vectors engineered from Tobacco mosaic virus and Semliki Forest virus and their evaluation as immunogens.
    Smith ML, Corbo T, Bernales J, Lindbo JA, Pogue GP, Palmer KE, McCormick AA.
    Virology; 2007 Feb 20; 358(2):321-33. PubMed ID: 17014881
    [Abstract] [Full Text] [Related]

  • 37. Essential role for virus-neutralizing antibodies in sterilizing immunity against Friend retrovirus infection.
    Messer RJ, Dittmer U, Peterson KE, Hasenkrug KJ.
    Proc Natl Acad Sci U S A; 2004 Aug 17; 101(33):12260-5. PubMed ID: 15297622
    [Abstract] [Full Text] [Related]

  • 38. In vivo anti-tumour activity of recombinant MVM parvoviral vectors carrying the human interleukin-2 cDNA.
    El Bakkouri K, Servais C, Clément N, Cheong SC, Franssen JD, Velu T, Brandenburger A.
    J Gene Med; 2005 Feb 17; 7(2):189-97. PubMed ID: 15515141
    [Abstract] [Full Text] [Related]

  • 39. Development of a second-generation oncolytic Herpes simplex virus expressing TNFalpha for cancer therapy.
    Han ZQ, Assenberg M, Liu BL, Wang YB, Simpson G, Thomas S, Coffin RS.
    J Gene Med; 2007 Feb 17; 9(2):99-106. PubMed ID: 17256802
    [Abstract] [Full Text] [Related]

  • 40. Induction of neutralizing antibodies and T cell responses by dengue virus type 2 envelope domain III encoded by plasmid and adenoviral vectors.
    Khanam S, Khanna N, Swaminathan S.
    Vaccine; 2006 Oct 30; 24(42-43):6513-25. PubMed ID: 16860446
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.